Cancer immunotherapy company Surface Oncology's $35m Eli Lilly, Amgen and Novartis-backed series A round demonstrates the recent success of oncology companies in the venture capital market.
Surface Oncology, a US-based startup developing immunoetherapies for cancer, raised $35m on Thursday in a series A round that provided more evidence of the ongoing funding success being experienced by oncology companies at present.
Lilly Ventures, the corporate venturing unit of pharmaceutical firm Eli Lilly, co-led the round with venture capital firm Atlas Venture, which funded Surface’s seed round last year, as well as Fidelity Biosciences, one of financial services firm Fidelity’s investment units, and VC firm New Enterprise Associates.
…
